Devin Incerti
Title
Cited by
Cited by
Year
Short-term costs of preeclampsia to the United States health care system
W Stevens, T Shih, D Incerti, TGN Ton, HC Lee, D Peneva, GA Macones, ...
American journal of obstetrics and gynecology 217 (3), 237-248. e16, 2017
1522017
Assessing variation in the cost of palivizumab for respiratory syncytial virus prevention in preterm infants
A Shahabi, D Peneva, D Incerti, K McLaurin, W Stevens
PharmacoEconomics-open 2 (1), 53-61, 2018
202018
A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis
D Incerti, JR Curtis, J Shafrin, DN Lakdawalla, JP Jansen
Pharmacoeconomics 37 (6), 829-843, 2019
172019
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators
JP Jansen, D Incerti, A Mutebi, D Peneva, JP MacEwan, B Stolshek, ...
Journal of medical economics 20 (7), 703-714, 2017
172017
The lifetime health burden of delayed graft function in kidney transplant recipients in the United States
D Incerti, N Summers, TGN Ton, A Boscoe, A Chandraker, W Stevens
MDM policy & practice 3 (1), 2381468318781811, 2018
142018
R you still using excel? The advantages of modern software tools for health technology assessment
D Incerti, H Thom, G Baio, JP Jansen
Value in Health 22 (5), 575-579, 2019
132019
Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon β-1a
MA Frasco, T Shih, D Incerti, O Diaz Espinosa, DK Vania, N Thomas
Journal of medical economics 20 (10), 1074-1082, 2017
102017
Maternal and infant adverse outcomes associated with mild and severe preeclampsia during the first year after delivery in the United States
TGN Ton, MV Bennett, D Incerti, D Peneva, M Druzin, W Stevens, ...
American journal of perinatology 37 (04), 398-408, 2020
92020
Developing open-source models for the US Health System: Practical experiences and challenges to date with the open-source value project
JP Jansen, D Incerti, MT Linthicum
PharmacoEconomics 37 (11), 1313-1320, 2019
82019
Prognostic model to identify and quantify risk factors for mortality among hospitalised patients with COVID-19 in the USA
D Incerti, S Rizzo, X Li, L Lindsay, V Yau, D Keebler, J Chia, L Tsai
BMJ open 11 (4), e047121, 2021
7*2021
The optimal allocation of campaign funds in US House elections
D Incerti
Electoral Studies 56, 102-113, 2018
52018
Toward relevant and credible cost-effectiveness analyses for value assessment in the decentralized US health care system
JP Jansen, D Incerti, JR Curtis
Journal of managed care & specialty pharmacy 25 (5), 518-521, 2019
32019
Are regime changes always bad economics? Evidence from daily financial data
D Incerti, T Incerti
Unpublished manuscript]. Department of Political Science, Yale University, 2019
3*2019
hesim: Health Economic Simulation Modeling and Decision Analysis
D Incerti, JP Jansen
arXiv preprint arXiv:2102.09437, 2021
22021
A description of the IVI-RA model v1. 0
D Incerti, J Jansen
22018
Patterns and adoption of BRCA testing in ovarian cancer in the real world: Observations from flatiron health
L Meyer, JD Wright, MK Downer, D Incerti, P Luhn, I Dolado, ...
Gynecologic Oncology 159, 29-30, 2020
12020
The economic burden of kidney graft failure in the United States
J Sussell, AR Silverstein, P Goutam, D Incerti, R Kee, CX Chen, ...
American Journal of Transplantation 20 (5), 1323-1333, 2020
12020
Multi-state network meta-analysis of cause-specific survival data
JP Jansen, D Incerti, T Trikalinos
medRxiv, 2020
12020
Exploring Structural Uncertainty With An Open-Source Cost-Effectiveness Model For Rheumatoid Arthritis
D Incerti, JR Curtis, M Lorenzi, JP Jansen
Value in Health 20 (9), A751, 2017
12017
An Assessment of Long-term Healthcare Expenditure Risk using a Dynamic Bayesian Model
D Incerti
12015
The system can't perform the operation now. Try again later.
Articles 1–20